Navigation Links
More radionuclide therapy is better for prostate cancer patients
Date:11/1/2011

Reston, Va. (November 1, 2011) For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.

Approximately 50 percent of prostate cancer patients develop bone metastases that are predominately osteoblastic, that is, have the tendency to fracture resulting in serious morbidity. This type of bone metastasis often leads to chronic pain syndrome in prostate cancer patients; as many as 50 percent of prostate cancer patients with chronic pain syndrome are reported to receive inadequate pain treatment, which makes them candidates for radionuclide therapy.

The retrospective study, "Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis," reviewed cases of 60 patients with hormone-refractory prostate cancer. The patients, all of whom had more than five lesions documented by a bone scan, were divided into three groupsthose who received one therapy, two therapies or three or more therapies.

"Radionuclide therapy of bone metastases has been used for several decades for those with prostate cancer," noted lead author of the study Hans-Juergen Biersack, MD. "For this study, we developed 188Re-HEDP as a novel radiopharmaceutical whichdue to it is short half life of 19 hoursmakes sequential therapy possible."

The researchers found that post-treatment survival increased with the number of radionuclide therapies administered. Patients with progressive hormone-refractory prostate cancer receiving one therapy added 4.5 months, those receiving two therapies added 10 months, and those receiving three or more therapies improved their survival by 15.7 months. In addition, while the Gleason scoresa grading system used to evaluate the prognosis of men with prostate cancerfor each group were similar, the number of life-lost years for patients receiving three or more therapies was significantly lower.

In regards to pain reduction, no significant difference was found among those receiving 188Re-HEDP therapies. Pain reduction was achieved in 89.5 percent of those receiving one therapy, in 94.7 percent of those receiving two therapies and in 90.9 percent of those receiving three or more therapies.

"For patients failing chemotherapy or hormone treatments, 188Re-HEDP is a promising therapy that can both extend the number of survival years and help relieve pain from bone metastases," noted Biersack. "The findings support and expand the role of molecular therapy with radioisotopes in oncology."

188Re-HEDP is not commercially available and in-house production is required. 188Re-HEDP treatments for this study were developed at Oak Ridge National Laboratory in Oak Ridge, Tenn.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Benefits of radionuclide therapy for neuroendocrine tumors
2. Radionuclide treatment against small tumors and metastases
3. New Multiple Sclerosis Therapy Promising in Early Trial
4. New therapy shows promise for treating cardiovascular disease
5. Speech Therapy Key to Stroke Rehab, But Many Miss Out
6. Scientists make strides toward drug therapy for inherited kidney disease
7. Ovarian Tumors May Develop Years After Fertility Therapy
8. Statin therapy fails to slow progression of atherosclerosis in pediatric lupus patients
9. Through-the-nipple breast cancer therapy shows promise in early tests
10. Compound found in common wart treatment shows promise as leukemia therapy
11. Timing for clinical trials for stem cell therapy in spinal cord injuries is right
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... , ... June 23, 2017 , ... ... surgeon practicing in Newburgh, New York, has recently begun offering three new minimally ... offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today ... is located at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). ... Restaurant Group who owns three other locations in the Topeka and Bonner Springs, Kan. ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will ... 20. , The two-day conference is focused on advancing scientific knowledge about the ... lives and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable ...
(Date:6/23/2017)... ... 23, 2017 , ... PureLife Dental is pleased to announce that California Dental ... As part of the amalgam separator endorsement, all CDA members may purchase an ECO ... the retail value. This partnership between PureLife and CDA is especially timely as it ...
(Date:6/23/2017)... San Francisco, CA (PRWEB) , ... June 23, 2017 , ... ... Conference on 26th June, 2017 from 9 am to 3 pm to present to ... curriculum. The program is an original curriculum project led by The Health Improvement ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
(Date:5/30/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will present ... Conference on Tuesday, June 13, 2017, in Rancho ... president and chief executive officer, is scheduled to present at ... can be accessed at http://ir.hill-rom.com/events.cfm . A recorded replay ... event through September 13, 2017. ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
Breaking Medicine Technology: